We uncovered a positive association between IL-2RG expression and the prognosis of cancer patients undergoing various immunotherapy treatments, including those involving anti-PD1, anti-PD-L1, and anti-CTLA-4 (Fig. 6F). Here, IL2RG is linked to cancer.